These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10587413)

  • 1. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study.
    Bratton DL; Lanz MJ; Miyazawa N; White CW; Silkoff PE
    Pediatr Pulmonol; 1999 Dec; 28(6):402-7. PubMed ID: 10587413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma.
    Sandrini A; Ferreira IM; Gutierrez C; Jardim JR; Zamel N; Chapman KR
    Chest; 2003 Oct; 124(4):1334-40. PubMed ID: 14555563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma.
    Fritscher LG; Rodrigues MT; Zamel N; Chapman KR
    Respir Med; 2009 Feb; 103(2):296-300. PubMed ID: 18805684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis.
    Hung CH; Hua YM; Hsu WT; Lai YS; Yang KD; Jong YJ; Chu YT
    Pediatr Int; 2007 Jun; 49(3):322-7. PubMed ID: 17532829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma.
    Lee MY; Lai YS; Yang KD; Chen CJ; Hung CH
    Pediatr Int; 2005 Dec; 47(6):622-6. PubMed ID: 16354213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Airway mechanics after withdrawal of a leukotriene receptor antagonist in children with mild persistent asthma: Double-blind, randomized, cross-over study.
    Kim JH; Lee S; Shin YH; Ha EK; Lee SW; Kim MA; Yoon JW; Baek HS; Choi SH; Han MY
    Pediatr Pulmonol; 2020 Dec; 55(12):3279-3286. PubMed ID: 32965787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma.
    Montuschi P; Mondino C; Koch P; Ciabattoni G; Barnes PJ; Baviera G
    Chest; 2007 Dec; 132(6):1876-81. PubMed ID: 18079221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children.
    Ghiro L; Zanconato S; Rampon O; Piovan V; Pasquale MF; Baraldi E
    Eur Respir J; 2002 Sep; 20(3):630-4. PubMed ID: 12358339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.
    Knuffman JE; Sorkness CA; Lemanske RF; Mauger DT; Boehmer SJ; Martinez FD; Bacharier LB; Strunk RC; Szefler SJ; Zeiger RS; Taussig LM;
    J Allergy Clin Immunol; 2009 Feb; 123(2):411-6. PubMed ID: 19121860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluticasone 250 microg/salmeterol 50 microg and montelukast on exhaled nitric oxide in asthmatic patients.
    Gelb AF; Taylor CF; Shinar CM; Gutierrez CA; Zamel N
    Can Respir J; 2008; 15(4):193-8. PubMed ID: 18551200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
    Lanz MJ; Eisenlohr C; Llabre MM; Toledo Y; Lanz MA
    Ann Allergy Asthma Immunol; 2001 Oct; 87(4):283-8. PubMed ID: 11686419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma.
    Kanniess F; Richter K; Janicki S; Schleiss MB; Jörres RA; Magnussen H
    Eur Respir J; 2002 Nov; 20(5):1080-7. PubMed ID: 12449158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma.
    Kanniess F; Richter K; Böhme S; Jörres RA; Magnussen H
    Eur Respir J; 2002 Oct; 20(4):853-8. PubMed ID: 12412675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxide as outcome measures.
    Verini M; Peroni DG; Piacentini GL; Nicodemo A; Rossi N; Bodini A; Chiarelli F; Boner AL
    Allergy Asthma Proc; 2007; 28(6):691-4. PubMed ID: 18201433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old.
    Straub DA; Minocchieri S; Moeller A; Hamacher J; Wildhaber JH
    Chest; 2005 Feb; 127(2):509-14. PubMed ID: 15705989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
    Wilson AM; Dempsey OJ; Sims EJ; Lipworth BJ
    Chest; 2001 Apr; 119(4):1021-6. PubMed ID: 11296164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma.
    Zeiger RS; Szefler SJ; Phillips BR; Schatz M; Martinez FD; Chinchilli VM; Lemanske RF; Strunk RC; Larsen G; Spahn JD; Bacharier LB; Bloomberg GR; Guilbert TW; Heldt G; Morgan WJ; Moss MH; Sorkness CA; Taussig LM;
    J Allergy Clin Immunol; 2006 Jan; 117(1):45-52. PubMed ID: 16387583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory markers as exacerbation risk factors after asthma therapy switch from inhaled steroids to montelukast.
    Ciółkowski J; Mazurek H; Hydzik P; Stasiowska B
    Pulm Pharmacol Ther; 2016 Aug; 39():7-13. PubMed ID: 27234706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children.
    Carrà S; Gagliardi L; Zanconato S; Scollo M; Azzolin N; Zacchello F; Baraldi E
    Respir Med; 2001 Sep; 95(9):734-9. PubMed ID: 11575894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of stromal cell-derived factor-1 and exhaled nitric oxide in asthmatic children following montelukast and ketotifen treatment.
    Hung CH; Jong YJ; Hua YM; Li CY; Lai YS; Yang KD; Chang HC
    Pulm Pharmacol Ther; 2007; 20(3):233-9. PubMed ID: 17276712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.